BD SurePath Direct Launched: BD Life sciences-Diagnostic Systems launched BD Surepath Direct to Slide, a liquid based Cytology (LBC) test intended to be used for screening and detection of cervical cancer. Cervical cancer is the second most common cancer in the country. This test is also intended for pre-cancerous lesions, atypical cells and all other cytological categories.
BD SurePathDirect to Slide is a LBC technique that will offer availability of residual sample for conducting important additional follow up tests without the need for repeat sampling. The Cervical cancer is most common in women aged between 15 and 44 years. There is no awareness among most women in the country regarding screening, especially while still asymptomatic.
According to Dr. Minaxi Desai, Ex-Director, Manchester Cytology Centre, cervical cancer can be prevented by screening women systematically through organized population-based programmes. LBC also offers the advantage of higher accuracy, shorter screening time and subsequent molecular studies on the same sample
“Women undergoing screening should opt for liquid based Cytology as a screening test since it has demonstrated ability to detect abnormal cells at the initial stages of precancer thus, preventing cervical cancer from progressing and ensuring cure which detected and treated early enough,” said Dr. Minaxi Desai- Ex Director, Manchester Cytology Centre, Manchester Royal Infirmary, UK.
“Liquid based cytology significantly increases the detection rate of cervical cancer compared to conventional PAP even at initial stages. With the launch of DTS, access to quality cervical cancer screening will increase and we recommend that an early diagnosis through screening by LBC can significantly enhance the chances of timely and successful treatment,” said Dr. Jaideep Malhotra, President-FOGSI 2018.
For More Latest Updates: Follow PressKS